FDA advisers back Johnson & Johnson COVID booster shots
New CDC data suggests the single-shot vaccine has the highest rate of breakthrough infections.
Alexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19. Previously, he was a campaign reporter for CBS News based out of Las Vegas, where he was raised. He covered presidential, Senate and House candidates for the 2020 election cycle in Arizona, California, Nevada and New Mexico. He has also worked in Washington for "Face the Nation" and in New York for the "CBS Evening News." Tin graduated from Columbia University in 2017 with a bachelor's degree in political science.
New CDC data suggests the single-shot vaccine has the highest rate of breakthrough infections.
The committee is also scheduled to vote on Johnson & Johnson's request tomorrow.
The uptick comes as the Biden administration touts new vaccination requirements.
Rural adults are among the most likely to say they would "definitely not" get vaccinated, according to a recent poll.
More than 22,000 pregnant Americans have been hospitalized with COVID-19, and data suggests 97% of them were unvaccinated.
New study analyzed early reports from thousands of Americans who received an additional dose already.
The CDC director defended the decision, after differing on one key point with a panel of vaccine advisers
Third doses of the Pfizer vaccine could be available to seniors and other at-risk groups this week.
Third doses could roll out this week, pending a review by CDC advisers
When can kids get vaccinated? Are Delta variant symptoms worse?
Some states fear their need for the potentially lifesaving treatment will outpace allocations from the federal government.
The panel had initially rejected by a majority vote over Pfizer's request for full approval of a booster.
Some COVID-19 "long-haulers" report struggling with debilitating symptoms for months after their initial infection.
Three studies published by the agency show booster shots could be needed soon.
Effectiveness in preventing hospitalization dropped to 80% among patients at least 75 years of age.